Resumen
En este artículo describimos una inmunoterapia para el cáncer que utiliza el activador de las células dendríticas denominado esqueleto de la pared celular del BCG (BCG-CWS) y el activador de las células NK, espirulina. En las células dendríticas, el blanco para el BCG-CWS está constituido por los receptores tipo Toll 2 y 4 que inducen a los linfocitos T citotóxicos (LTC) específicos de tumor a eliminar la población tumoral con aumento de la expresión del complejo mayor de histocompatibilidad (CMH). Por el contrario, la espirulina actúa directamente sobre las células NK para remover la población tumoral con expresión baja del CMH.
Palabras clave
Terapia inmune, receptores tipo Toll, adyuvancia, células dendríticas, vacuna
Clasificación en siicsalud
Artículos originales> Expertos del Mundo>
página www.siicsalud.com/des/des049/06810000.htm
Especialidades
Principal: Oncología
Relacionadas: Inmunología, Medicina Interna
Enviar correspondencia a:
Tsukasa Seya, Hokkaido University, Graduate School of Medicine, 060-8638, Sapporo, Japón
Patrocinio y reconocimiento
Los autores agradecen a los Dres. Takagaki, Aoki y Abe (Dainippon Ink Co. ltd) por el apoyo a este trabajo.
Patrocinio: Osaka Community Foundation (patrocinio parcial).
Artículo completo
(castellano)
Extensión:
+/- 3.33 páginas impresas en papel A4
Exclusivo para suscriptores/ assinantes |
NEW IMMUNE THERAPY FOR CANCER USING MICROBIAL SUBSTANCES
Abstract
Here we offered an immunotherapy for cancer using a dendritic cell activator BCG-cell wall skeleton (CWS) and an NK activator spirulina. The target on dendritic cells for BCG-CWS is Toll-like receptors 2 and 4, that induces tumor-specific CTL to eliminate MHC-high tumor population. In contrast, spirulina acts directly on NK cells to remove MHC-low tumor population. The results were approved in syngeneic tumor-implanting mice and expected in patients with post-operative cancer in the hospital of Osaka Medical Center for Cancer.
Key words
Toll-like receptors, adjuvant, dendritic cells, immunotherapy, vaccine
Full text
(english)
para suscriptores/ assinantes
|
Bibliografía del artículo
1. Hayashi A, Doi O, Azuma I, Toyoshima K. Immunofriendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients. Proc Japan Acad 1998; 74(B):50-58.
2. Akazawa T, Masuda H, Saeki Y, Matsumoto M, Takeda K, Akira S, Azuma I, Toyoshima K, Seya T. Adjuvant-mediated tumor regression and tumor-specific CTL induction are impaired in MyD88-deficient mice. Cancer Res 2004; 64:757-764.
3. Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, Matsumoto M, Ohteki T, Kaisho T, Takaoka A, Akira S, Seya T, Taniguchi T. Selective contribution of IFN- signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infectin. Proc Natl Acad Sci USA 2003; 100:10872-10877.
4. Matsuo-Tanabe M, Kawamoto T, Tanida S, Matsumoto M, Seya T. Toll-like receptor 2 agonists with unique properties synthesized with reference to a product of Streptosporangium. Immunology 2004 pp. 235-241.
5. Uehori J, Tsuji S, Matsumoto M, Kawata C, Takeuchi T, Akira S, Azuma I, Toyoshima K, Seya T. Simultaneous blocking of human Toll-like receptor 2 and 4 suppresses myeloid dendritic cell maturation induced by Mycobacterium bovis bacillus Calmette-Guérin (BCG)-peptidoglycan (PGN). Infect Immun 2003; 71:4238-4249.
6. Masuda H, Akazawa T, Ebihara T, Hazeki K, Matsumoto M, Seya T. Anti-tumor natural killer cell activation induced by spirulina extract. Cancer Science (submitted).
7. Hirahashi T, Matsumoto M, Hazeki K, Saeki Y, Ui M, Seya T. Activation of the human innate immune system by spirulina: Augmentation of interferon gamma production and NK cytotoxicity by oral administration of spirulina. Int Immunopharmacology 2002; 2:423-434.
8. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T. Maturation of human human dendritic cells by cell-wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin: involvement of Toll-like receptors. Infect Immun 2000; 68:6883-6890.
9. Seya T, Akazawa T, Matsumoto M, Begum NA, Azuma I, Toyoshima K. Innate immune therapy for cancer: application of BCG-CWS and spirulina to patients with lung cancer. Anticancer Res 2003; 23:4369-4376.
10. Seya T, Akazawa T, Tsujita T, Matsumoto M. Application of Toll-like receptor agonists to vaccine adjuvant therapy. eCAM Feb issue (review) 2006.
|
|
